{"entity":{"id":"nct06116136","kind":"trial","name":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in gastric & gastro-oesophageal junction cancer, run by Servier Bio-Innovation LLC, active and no longer recruiting.","summary":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. is a phase 1/2 interventional study registered as NCT06116136 by Servier Bio-Innovation LLC, with 48 participants enrolled, started 2024-08-31 and due to reach its primary completion in 2027-08. Interventions recorded: S095029 and pembrolizumab 200 mg (KEYTRUDA ®).","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06116136","url":"https://clinicaltrials.gov/study/NCT06116136"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06116136","phase":"1/2","setting":"Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer","sponsor":"Servier Bio-Innovation LLC","enrolled":48,"outcomes":[]},"route":"/trials/nct06116136/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}